This inventor holds 40 USPTO granted patents and 34 published patent applications, primarily in Muscle Targeting Complexes. Top assignees: Dyne Therapeutics, Inc., Hercules Capital, Inc., as Agent. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2026
Areas of Expertise:
Title: Cody A. Desjardins: Innovator in Molecular Treatment for Dystrophinopathies
Introduction
Cody A. Desjardins is an accomplished inventor based in Waltham, Massachusetts, with a notable portfolio comprising 22 patents. His contributions to the field of molecular therapeutics have significantly impacted the treatment of dystrophinopathies, diseases that affect muscle function due to issues with the dystrophin protein.
Latest Patents
Among his latest inventions is a groundbreaking patent focused on muscle-targeting complexes designed for the treatment of dystrophinopathies. This innovation involves complexes that combine a muscle-targeting agent, which covalently links to a molecular payload. The muscle-targeting agent specifically binds to receptors on muscle cells, ensuring an effective delivery system. The molecular payload is designed to enhance the expression or functionality of a functional dystrophin protein, utilizing oligonucleotides such as antisense oligonucleotides that promote exon skipping in mRNA from a mutant DMD allele.
Career Highlights
Cody currently works at Dyne Therapeutics, Inc., where he applies his expertise in molecular therapies to advance treatment options for those suffering from muscle diseases. With 22 patents to his name, his career reflects a commitment to innovation and improvement in therapeutic practices.
Collaborations
Throughout his career, Cody has collaborated with talented professionals including Mohammed T. Qatanani and Timothy Weeden. These partnerships highlight the importance of teamwork in the research and development of cutting-edge treatments.
Conclusion
Cody A. Desjardins represents the forefront of innovation in molecular treatment for dystrophinopathies. His extensive patent portfolio and collaborative spirit illustrate his dedication to improving patient outcomes and advancing scientific knowledge in the field of muscle-targeting therapies. As he continues to develop new solutions, his work will undoubtedly pave the way for future breakthroughs in the treatment of muscular diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile